Clomiphene Citrate Market will grow at 5.4% CAGR, to be valued at US$ 14.51 Million by 2027 – Coherent Market Insights
SEATTLE, April 29, 2021, (PHARMIWEB) — Global Clomiphene Citrate Market
Clomiphene citrate is an oral medicine used to treat infertility in both men and women. Hormonal disorders, tubal disorders, uterine disorders, ovarian disorders, and endometriosis are the major cause of female infertility, whereas erectile dysfunction, ejaculation disorders, varicocele, and azoospermia are the major cause of male infertility. Chloramiphene, Chloramifene, Clomifene, and Clomid are some of the other names of clomiphene citrate. However, clomiphene citrate is not recommended for women whose ovaries no longer produce eggs properly.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4140
The outbreak of COVID-19 has caused a huge impediment to the demand for clomiphene citrate because women who were under clomiphene citrate treatment tested positive for COVID-19. Thus, they have to suspend the treatment, according to the American Society for Reproductive Medicine (ASRM). However, according ASRM report of March 2020, women with COVID-19 have given birth to babies without COVID-19 infection. It is not a fatal infection for a pregnant women.
High prevalence of infertility worldwide is expected to augment growth of the global clomiphene citrate market growth during the forecast period. According to the United States Centers for Disease Control and Prevention (CDC), 2018 report, around 6% of women in the U.S., aged 15 to 44 years, were unable to conceive after one year of intercourse. Moreover, in 2017, around 12% of women in the U.S., aged 15 to 44 years, were unable to conceive or carry a pregnancy till child birth. Furthermore, in 2017, around 9% of men in the U.S., aged 25 to 44 years, required medical help for reproduction, according to the same source.
Moreover, increasing prevalence of polycystic ovary syndrome (PCOS) is expected to propel the global clomiphene citrate market growth.
Inability of clomiphene citrate to achieve pregnancy compared to other drugs, such as Letrozole, and side effects of clomiphene citrate are expected to hamper the global clomiphene citrate market growth over the forecast period. For instance, in 2014, researchers at the National Institutes of Health (NIH) found that women treated with Letrozole showed higher rates of ovulation and live births compared to women treated with clomiphene citrate.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4140
- Secondary Amenorrhea
- Amenorrhea Galactorrhea Syndrome
- Psychogenic Amenorrhea
By Distribution Channel:
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
- Latin America
- Middle East
- North America
- Asia Pacific
North American region is expected to witness significant growth in the global clomiphene citrate market owing to the increasing incidence of polycystic ovary syndrome (PCOS) in the region. According to CDC, in the U.S., PCOS affects around 5 million women of reproductive age, while, more than half of the women develop type 2 diabetes by age 40.
Europe is also expected to show robust growth in the global clomiphene citrate market due to the presence of major players in the region. Market players are adopting various inorganic strategies to strengthen their market position.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/clomiphene-citrate-market-3407
Major players active in the global clomiphene citrate market are Shanghai Trifecta Pharma Co. Ltd, Par Pharmaceutical, Sanofi S.A., Merck & Co. Inc., Cipla Inc., Unichem Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Emcure Pharmaceuticals Ltd., Incepta Pharmaceuticals Ltd., and Serum Institute of India Pvt. Ltd.About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire